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ABSTRACT
Background. Many women covered by the Spanish public
health system also have an extra private insurance policy
for gynecological examinations and routine annual mam-
mography. We retrospectively analyzed the long-term
survival rates in these patients when diagnosed with breast
cancer.
Methods. We analyzed the survival and prognostic factors
in patients diagnosed with breast cancer who were referred
to a medical oncology unit for multidisciplinary treatment
covered by private health insurance.
Results. Between 1994 and 2009, a total of 434 patients
with breast tumor were analyzed: 33 in situ and 401 infil-
trating. Among the infiltrating carcinomas, 38 were stage
IV and 363 were stage I, II, or III. With a median follow-up
of 62 months, the 5-year global survival rate was 91 %:
97 % for stage I, 94 % for stage II, and 77 % for stage III
tumors. In the patients diagnosed by routine mammogra-
phy, the 5-year survival rate was 96 %, compared with
86 % in those consulting their gynecologist after breast
self-examination or for other symptoms (p = 0.0159).
Seventy-four percent were treated conservatively and
experienced better survival than the 26 % who underwent
mastectomy (p = 0.0024). Patients with disease with
positive hormone receptors had a better survival rate
(p = 0.0264); hormone receptor status was the only inde-
pendent prognostic factor in the Cox multivariate analysis.
Postmenopausal patients who received adjuvant tamoxifen
plus exemestane had a better prognosis than those who
received tamoxifen alone (p = 0.0203).
Conclusions. Long-term survival rate was high in breast
cancer patients with extra private insurance coverage. This
is probably because disease was diagnosed at an early
stage.
The data provided by the Spanish Oncology Society and
published in the EUROCARE 4 study estimated that
19,430 new cases of cancer would have been diagnosed in
Spain in 2010.1 The 5-year survival rate in breast cancer
patients in Spain is estimated to be around 70 %, a figure
similar to that found in the rest of Europe. Most of these
patients are treated under the Spanish European-style
public health system, which provides universal coverage
for the population. The main complaints of service users
are the waiting lists and the delay in carrying out diagnostic
tests, such as mammography and biopsy, and surgery with
curative intent.
To speed up the diagnostic process, reduce surgery
waiting time, and receive better levels of comfort and
service, many users of the public health system also buy
extra private medical insurance. Insurance companies offer
an American-style range of health services for a monthly
payment. In the case of breast cancer, they offer the pos-
sibility of rapid diagnosis using image testing and biopsies
and access to curative surgery generally within a week.
They also offer treatments that improve patients’ psycho-
logical tolerance, such as conservative surgery or
immediate breast reconstruction. However, there are no
data about the association between breast cancer long-term
survival rates and private extra health insurance.
We performed a retrospective study of patients with
private extra health insurance referred to an oncology unit
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for treatment of breast tumors. We recorded patient char-
acteristics, tumor stage at the time of diagnosis, treatment
and its relation to clinical evolution, and survival in order
to compare these results with those experienced by patients
who receive care only via the public health system.
PATIENTS AND METHODS
Patients
We included all consecutive patients with histological
diagnosis of infiltrating or in situ carcinoma of the breast
who were referred to a medical oncology specialist for
multidisciplinary treatment. We followed the clinical
guides for diagnosis and treatment of breast cancer of the
National Comprehensive Cancer Network and the ESMO
Clinical Recommendations.2,3 We used the annual updates
and the publications of relevant studies, which have chan-
ged the treatment indications to achieve the highest level of
5-year survival rates and low morbidity and adverse effects.
Diagnostic Tests
The diagnostic tests were defined as ‘‘at the request of
the patient’’ when patients presented symptoms and as
routine screening tests (such as annual mammography)
requested by the gynecologist in women over the age of
40 years who had not presented symptoms or discovered a
breast tumor by self-palpation.
At the time of diagnosis, tumor histology, hormone
receptors, and other biological markers such as the HER2
gene were recorded to establish whether they were over-
expressed (positive) or not (negative).
Treatments
Multidisciplinary treatment was considered of palliative
or curative intent depending on the tumor stage at the time
of diagnosis and in accordance with the recommendations
of the clinical guidelines in use at the time.
Surgery in the initial stages of cancer comprised tu-
morectomy plus radiotherapy, except in cases of multifocal
tumors or tumors more than 3 cm in diameter, in which
case modified radical mastectomy (MRM) was performed.
The sentinel lymph node technique was introduced in 2004
and was used when indicated.4 When the sentinel lymph
node was invaded by tumor cells, axillary lymphadenec-
tomy was performed. Since 1998, whenever possible,
MRM has been completed with immediate or delayed
breast reconstruction.
Adjuvant axillary radiotherapy was performed in
patients with four or more positive lymph nodes in the
axillary node clearance and in all T3 and T4.
Until 2002, adjuvant chemotherapy consisted predomi-
nantly of CMF (cyclophosphamide, methotrexate,
5-fluorouracil) for stage I disease. Since then (and in all
stage II and III disease), we have used adjuvant anthracy-
cline-based chemotherapy.5,6 Since 2004, cases of axillary
lymph nodes with tumor invasion have also received tax-
anes (paclitaxel or docetaxel).7–9
Adjuvant hormone therapy comprised tamoxifen 20 mg/
day for 5 years in premenopausal subjects and for carci-
noma-in situ in the case of positive hormone receptors.10 In
postmenopausal subjects, 2 years of tamoxifen followed by
3 years of exemestane was preferred.11 Since 2004, after
5 years of adjuvant tamoxifen, postmenopausal patients
have received adjuvant letrozole between years 5 and 10.12
Since 2005, we have added adjuvant intravenous trast-
uzumab every 3 weeks for a year in patients with positive
HER2 identified by fluorescence in situ hybridization.13
For neoadjuvant treatment, we used anthracycline-based
chemotherapy with taxanes with or without trastuzumab,
depending on biological indicators.
Statistical Analyses
We used descriptive statistics to define patient charac-
teristics and used parametric and nonparametric tests, such
as Student’s t test and the Chi square test, to establish
differences. For the univariate analysis of survival and
disease-free interval, and response duration or progression-
free survival, we used Kaplan–Meier survival curves
compared with the log rank test. For the multivariate
analysis of prognostic factors, we used the Cox test.




Between 1994 and 2009, a total of 916 consecutive
patients were referred to the medical oncology facility. Of
these patients, 461 had a breast tumor. The patients had
private health insurance coverage, mainly with the firms
DKV Seguros (Munich Health), Asistencia Sanitaria Co-
legial, and Aresa-Mutua Madrilen˜a. All patients had a
histological or cytological diagnosis of infiltrating or in situ
breast carcinoma requiring complementary radiotherapy
with or without hormone therapy.
Of 461 patients with breast tumors, 27 consulted only to
obtain a second opinion and either received treatment at
other centers or were lost to follow-up. These patients were
excluded from the analysis. Of the 434 remaining patients,
33 (8 %) were diagnosed with carcinoma-in situ, and those
who were positive for hormone receptors were treated with
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tamoxifen for 5 years. The remaining 401 patients were
diagnosed with invasive carcinoma and received multidis-
ciplinary treatment in accordance with the clinical
guidelines in use at the time of diagnosis. Median age was
55 years (range 29–88 years).
Hormone receptors were positive in 339 (78 %) patients,
negative in 80 (18 %), and unknown in 15 (4 %). The
HER2 oncogene was determined in 292 patients (67 %); all
patients were treated after the year 2000, plus some who
were analyzed retrospectively. HER2 was positive in 68
(23 %) and negative in the remaining 224 (77 %).
The median follow-up of living patients was 62 months.
When the survival curves are broken down according to
disease stage, the disease-free survival rate after 5 years
was 100 % for carcinoma-in situ, 97 % for stage I disease,
94 % for stage II disease, 77 % for stage III disease, and
28 % for stage IV disease. The 5-year survival rate in these
patients, including those with stage IV disease and carci-
noma-in situ, was 80 %.
Surgery
In 343 patients treated with curative intent (without
metastasis), MRM was performed in 109 (32 %). MRM
was performed predominantly in cases of multifocal
tumors or in large tumors either because of the technical
difficulty or because of the patient’s decision. The
remaining 234 patients (68 %) received conservative
treatment of the breast with tumorectomy or quadrantec-
tomy with radiotherapy (or without radiotherapy in those
over the age of 70 years with positive hormone receptors).
In 16 patients (5 %), a second metachronous tumor was
diagnosed in addition to the synchronous bilateral neo-
plasms. Four of them developed a second contralateral
breast cancer, which was operated and treated like another
primary tumor. In the other 12 patients, cancer outside the
breast was diagnosed: two in the ovary, two in the endo-
metrium, two in the colon, two in the lung, one in the
esophagus, one in the cervix, one soft tissue sarcoma, and
one acute myeloblastic leukemia. All received multidisci-
plinary treatment with curative intent.
Three hundred fifty-seven of 434 patients (82 %) had
nonmetastatic infiltrating (invasive) carcinoma and
received multidisciplinary treatment. A total of 131
patients (37 %) presented a lump or tumor growth in the
breast that led them to consult a gynecologist. In 226
(63 %), the diagnosis was made by the gynecologist by
mammography and other imaging tests such as breast
ultrasound or magnetic resonance. In this group of patients,
the probability of 5-year survival was 96 % and remained
above 90 % after 10 years of follow-up. Survival was
significantly better than in patients who consulted their
gynecologist after self-detection of a breast lump or
another symptom of breast tumor (changes in the nipple,
inflammation of the skin, or local pain); in these patients,
the probability of 5-year survival was 86 % and above
80 % after 10 years (p = 0.0159) (Fig. 1).
Patients with stage I and II disease obtained the best
cure rates after 10 years—approximately 90 %, compared
with less than 50 % in those diagnosed with stage III dis-
ease. In the 265 patients out of the 357 (74 %) with
nonmetastatic infiltrating primary cancer who received
conservative treatment, life expectancy after 10 years was
above 95 % and overall survival was significantly better
than in the 92 patients (26 %) who received MRM, prob-
ably because the patients treated conservatively presented
earlier tumor stages at the time of diagnosis (p = 0.0024,
Fig. 2).
Neoadjuvant and Adjuvant Chemotherapy
In 34 of 264 (13 %) patients receiving chemotherapy for
the primary tumor, induction or neoadjuvant chemotherapy
was administered as the initial strategy as a result of the
locally advanced state of the tumor. In all cases, chemo-
therapy was anthracycline based; taxanes were introduced
in 1999 and in patients positive for HER2, trastuzumab in
2004. Overall survival was significantly better in the
patients treated with adjuvant chemotherapy (230 patients)
than in those treated with neoadjuvant chemotherapy
(p = 0.0197), probably as a result of the earlier stage of the
patients in the adjuvant treatment group. However, the cure
rate, above 75 % after 5 years in patients treated with
neoadjuvant chemotherapy, reflects the good prognosis
achieved with this strategy of initiating treatment with
chemotherapy (Fig. 3).
FIG. 1 Survival according to diagnosis: self-detection or routine
mammography
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Since 2004, of the 230 patients administered adjuvant
chemotherapy, 85 (37 %) received CMF, 101 (44 %)
anthracycline-based CT, 26 (11 %) anthracyclines plus
taxanes, and 18 (8 %) anthracyclines plus taxanes and
trastuzumab for a year due to HER2 overexpression. The
survival curves according to treatment were similar.
Adjuvant Hormone Therapy
Of the 357 patients with nonmetastatic infiltrating car-
cinoma receiving treatment with curative intent, 288 were
positive for hormone receptors and 62 were negative. In
seven patients, the receptor status was unknown. At the
time of the analysis, 48 % of positive receptor patients
were receiving hormone therapy. Survival was significantly
better in the hormone receptor-positive patients
(p = 0.0001) (Fig. 4).
Adjuvant hormone therapy for premenopausal women
with positive receptors was administered in 62 patients.
Seventy postmenopausal women also received this treat-
ment. Tamoxifen was administered to 91 patients for
2 years, followed by exemestane for three more years. A
combination of tamoxifen plus letrozole was administered
to 15 patients and anastrazole to 19 other patients. Hor-
mone therapy was not administered in four patients with
positive receptors as a result of intolerance or refusal on the
part of the patient.
In the two most numerous groups of postmenopausal
patients treated with adjuvant hormone therapy, overall
survival was significantly better in those who received
tamoxifen plus exemestane than in those treated with
tamoxifen alone (p = 0.0490) (Fig. 5).
HER2 Expression
Of the 254 patients in whom HER2 was determined, 200
were negative (that is, not presenting overexpression). Nine
of these patients died of tumor recurrence. Fifty-four other
patients were positive (that is, presenting overexpression).
Six of them died from disease progression. Survival in the
two groups demonstrated a trend toward statistical signif-
icance in favor of the negative patients (p = 0.0621), and
the 5-year survival rate was 95 %. However, HER2-posi-
tive patients also obtained a high 5-year survival rate
FIG. 2 Survival of patients treated with mastectomy or conservative
surgery
FIG. 3 Overall survival according to treatment strategy (adjuvant or
neoadjuvant chemotherapy)
FIG. 4 Overall survival in postmenopausal patients according to
hormone receptor status
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(84 %), probably as a result of the compensatory effect of
trastuzumab treatment.
Cox Multivariate Analysis
The Cox multivariate analysis included all the coded
variables that had resulted in statistical significance in the
univariate analysis. Of the four analyzed variables—self-
examination palpation versus mammography diagnosis, stage
I or II disease versus stage III disease, HER2 overexpression
versus no overexpression, or positive hormone receptors
versus negative—only the difference between the hormone
receptors remained statistically significant (p = 0.0019).
Stage IV
Thirty-nine of 434 patients (9 %) presented for the first
time with a diagnosis of stage IV breast cancer. Median
overall survival was 24 months. There were no significant
differences in survival between patients who presented
synchronous M1 at the time of diagnosis, and who therefore
received treatment for M1 but also for the primary tumor
(simple mastectomy, radiotherapy, etc.), and those who had
been treated for primary tumor previously at another center
and who later experienced recurrence (i.e., patients with
metachronous M1). In the first group, 12 of 18 patients died,
and in the second 18 of 20; the differences in survival in the
two groups were not significant (p = 0.123).
Comparison with Another Database
We compared our results with those published by EU-
ROCARE in a similar geographic area (Granada, Spain).14
These patients did not have private health insurance. The
5-year survival analysis was staged according to one of five
categories: small, node-negative (T1N0M0); large, node-
negative (T2-3N0M0); node positive (T1-3N_M0, regard-
less of the number and anatomic level of the involved
axillary nodes); locally advanced (T4NxM0, large tumors
with skin/chest wall involvement, regardless of nodal sta-
tus); and metastatic (M1) and of unspecified stage.
The 5-year survival rates by stage group in the EURO-
CARE study were 98, 82, 66, 63, and 46 %, respectively.
In our study, they were 97, 93, 84, 78, and 21 %,
respectively.
DISCUSSION
To our knowledge, this is the first report of the prognosis
of breast cancer in patients who are entitled to receive
health care through the public health system but who also
have private insurance because of the subjective impres-
sion that it is more convenient and efficient. The first
striking finding in this group of patients is that two-thirds
were diagnosed with stage I or II disease. In a study con-
ducted in a public health system in Granada, 37 % of
patients were diagnosed with initial stage tumors, com-
pared with 83 % in our series.14 In spite of the differences
in the presentation of the data, the large disparity between
the results suggests a clear predominance of initial stages in
our study. This finding may be linked to the good prognosis
of these patients, with 5-year survival rates of above 90 %.
The high rate of patients without clinical symptoms in
whom breast cancer was detected during routine mam-
mography underlines the effectiveness of the private care
system, thanks to the use of annual screening for breast
tumor detection and the application of standard multidis-
ciplinary treatment.
No precise comparisons can be made with other public
health systems because of the lack of statistical data, but our
results suggest that the long-term survival rate for breast
cancer is high in patients who take out extra private health
insurance. This good prognosis may be due in part to a
higher level of motivation among these patients, which leads
them to request regular examinations and to comply well
with treatment, but it must also be attributed to the rapid,
effective response on the part of the private health system.
The use of a conservative treatment regimen is less
traumatic for patients and demonstrates that the practical
application of the knowledge obtained from clinical trials
can offer the good results expected in a nonselected patient
population.15 For example, patients with locally advanced
cancer and a relatively poor prognosis achieve cure rates
above 80 % when they receive neoadjuvant chemotherapy.
Similarly, HER2-positive patients have a relatively good
prognosis after the administration of adjuvant trastuzumab,
FIG. 5 Overall survival in postmenopausal patients treated with
tamoxifen or with tamoxifen plus exemestane
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and postmenopausal patients treated with tamoxifen fol-
lowed by adjuvant exemestane have a better prognosis than
those treated with tamoxifen alone.
In our view, the most relevant finding is the good
prognosis of patients diagnosed with breast cancer by
mammography before the appearance of local tumor
symptoms. In this regard, the availability of early breast
cancer testing offered under private insurance policies is
particularly useful in places where the public system does
not provide this service.
As in any retrospective study, many points are still to be
resolved and analyzed, such as the psychological reper-
cussions of effective and more conservative treatments, and
the additional advantages that private health coverage can
offer.
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